Articles tagged with Prostate Cancer
Researchers identified SPINK1 as a biomarker for an aggressive type of prostate cancer that accounts for 10% of cases. The discovery could lead to a simple urine test to diagnose this variation, which tends to recur quickly.
Researchers at OHSU Cancer Institute found that Ipilimumab effectively stimulates the immune system to fight prostate cancer, particularly in patients with resistant tumors. The drug works by blocking CTLA-4, releasing the safety brake and allowing the immune response to have a stronger anti-tumor effect.
Researchers found that metastatic prostate tumors produce significant levels of testosterone, fueling cancer growth despite low circulating androgen levels. This discovery suggests targeting the tumor itself, rather than systemic hormone suppression, to develop more effective treatments for all stages of prostate cancer.
Researchers at Jefferson University have identified a key signaling protein that enables prostate cancer cells to metastasize. Blocking this protein, Stat3, can prevent prostate cancer from spreading, offering new potential therapies.
Researchers at OHSU Cancer Institute found that Sagopilone, a novel chemo drug, significantly reduced PSA levels and showed positive results in some cases of advanced prostate cancer. The study involved men with androgen-independent prostate cancer that has metastasized.
Researchers found that FruHis, a carbohydrate in dehydrated tomato products, has strong protective effects against prostate cancer. The study shows that a diet rich in tomato paste and FruHis led to the longest survival rate among rats with prostate cancer.
A recent study suggests that dehydrated tomato products containing the organic carbohydrate FruHis may have strong anti-cancer properties. In an animal study, rats fed with a diet rich in FruHis and tomato paste showed longer survival from cancer compared to those without these ingredients.
A recent analysis found that most US health news stories have major failings in reporting, including inadequate discussion of costs, harms, and benefits. The study graded 500 US health news stories, resulting in a high rate of poor reporting, highlighting the need for improved standards in health journalism.
Researchers analyzed vitamin D concentrations in 749 men with prostate cancer and 781 without, finding no correlation between vitamin D levels and prostate cancer risk. However, higher vitamin D levels were associated with increased risks of aggressive disease, but the association was not statistically significant.
Researchers have found estrogen-dependent molecular pathways play a crucial role in regulating aggressive prostate cancer. The study used innovative technology to analyze 455 prostate cancer samples and identified an 87-gene expression signature that distinguishes fusion-positive TMPRSS2-ERG cancers from other malignancies.
Researchers at Thomas Jefferson University have developed a new ultrasound technique that targets areas of increased blood flow in the prostate gland, significantly reducing the number of unnecessary biopsies. The study found that targeted biopsies were twice as likely to detect cancer compared to conventional methods.
An experimental drug, OSU-HDAC42, has blocked prostate cancer progression in mice with an aggressive form of the disease. The agent reactivates genes that normally protect against cancer, shifting tumor progression to a more benign direction.
A re-analysis of PCPT data reveals that finasteride significantly reduces the incidence of prostate cancers, including higher-grade ones. The study also suggests that finasteride may suppress indolent cancers and could be useful in determining tumor aggressiveness.
A new study shows that DCE-MRI plus DWI can accurately diagnose residual or recurrent prostate cancer, improving patient outcomes. The two imaging studies have a combined accuracy rate of about 72% in detecting cancer after HIFU ablation.
Researchers have identified a specific gene expression profile of prostate cancer stem cells, revealing key pathways and potential therapeutic targets. The study's findings offer new hope for treatments targeting the rare but aggressive cancer stem cells.
New data suggests finasteride may be more effective than previously thought in preventing prostate cancer. The study analyzed over 18,000 men and found a significant reduction in aggressive tumors and an increased prevention of clinically significant disease.
A new study reveals that prostate cancer screening programs and access to urologists are significantly linked to reduced mortality rates. The research, presented at the AUA 2008 conference, found that higher urologist population densities and PSA screening rates correlate with lower mortality rates.
A study published in Clinical Cancer Research found that genetic polymorphisms are associated with a lower risk of prostate cancer among Hispanic men. The research suggests that these genetic variations may help clinicians predict who is more likely to develop the disease, potentially reducing unnecessary screenings and treatments.
Men aged 75-80 with PSA levels below 3 ng/ml are unlikely to develop aggressive disease and may safely discontinue screening. The study's findings could lead to a reduction in unnecessary treatment for non-aggressive prostate cancers.
A new study strengthens the association between exposure to Agent Orange and an increased risk of developing prostate cancer in aging Vietnam veterans. The study found that twice as many exposed men were diagnosed with prostate cancer, diagnosed at a younger age, and more likely to present with aggressive disease.
Researchers found a 27% reduced incidence of prostate cancer in mice on a low-fat diet compared to those on a Western-style diet. The study suggests that lowering dietary fat intake may slow the growth of precancerous cells and prevent prostate cancer development.
Researchers found that a single PSA reading taken at age 44-50 can predict prostate cancer diagnosis up to 30 years subsequently, even in men below age 40. The study suggests possible prolonged periods of prostate cancer pre-malignancy and the relationship between PSA and advanced cancer development.
A study found that external-beam radiation therapy for localized prostate cancer increases the rate of secondary malignancies, including a 3.0-fold increase in bladder cancer, compared to radical prostatectomy. This predisposition is observed in lung-cancer resections and rectal cancer as well.
Only a small proportion of diagnosed low-risk prostate cancers will progress to life-threatening disease during a patient's lifetime. Recorded incidence has increased due to screening and improved diagnosis, but mortality rates have not kept pace, suggesting that most low-risk cases may remain stable or even decrease over time.
Researchers found that African-American men with a family history of prostate cancer are unlikely to develop the disease if their baseline PSA level is below the age-specific median. In contrast, those with high baseline PSA levels are more likely to develop prostate cancer, even with other risk factors.
Two studies presented at AUA 2008 found that active surveillance is a viable option for low-risk prostate cancer patients. The studies highlighted the importance of reliable clinical predictors of disease progression and showed that endorectal MRI was the most reliable predictor of disease progression.
A new therapeutic vaccine has shown promising results in prolonging survival and improving the quality of life for men with metastatic prostate cancer. The adenovirus/PSA vaccine demonstrated strong immune responses to PSA, leading to improved patient outcomes.
Researchers have found a biomarker that can distinguish between HG-PIN lesions destined to become cancerous and those that will remain benign. The PTOV1 gene marker is linked to prostate cancer development and can help determine which men with HG-PIN are at substantial risk of developing prostate cancer.
Researchers found a link between PTOV1 gene expression and prostate cancer development in HG-PIN lesions. The study suggests using the biomarker to determine which men with HG-PIN are at substantial risk of developing prostate cancer, potentially saving up to 40% of unnecessary biopsies.
A new study suggests that therapies inhibiting IGF-1 signaling in prostate cancer may not work as expected in tumors with a compromised p53 gene. The research, conducted by investigators at Fred Hutchinson Cancer Center, found that eliminating IGF-1R expression led to hyperplastic cell growth and proliferation in mouse prostates.
A prostate cancer screening program introduced in the Tyrol region of Austria led to a significant reduction in deaths from the disease, with a 54% decline by 2005. The program's success can be attributed to early detection and effective treatment, which has improved patient outcomes.
A study by OHSU Cancer Institute researcher Tomasz Beer found that a protein called C-reactive protein can predict the survival rate of men with advanced prostate cancer. The discovery could lead to a simple blood test to help patients and doctors understand the disease's progression.
Researchers are using cellular strategies and new vaccines to direct the body's immune system against cancer. A phase I/II trial of a live Listeria cancer vaccine has shown that it is safe for humans and can reduce tumor size in some patients, with three women experiencing approximately 20 percent tumor reductions.
Researchers have found genetic differences in breast tumors between African-American and Caucasian women that may contribute to the more aggressive clinical features of breast cancer in African-American women. These differences were also seen in prostate cancer, suggesting a possible link to viral involvement and genetic factors.
A recent study found that 3T MRI without an endorectal coil can detect prostate cancer with diagnostic image quality and accurate tumor localization. The technique provided undistorted images of the prostate and surrounding tissue, allowing for precise surgical planning.
Scientists at the University of Michigan have identified six new genes that play a role in type 2 diabetes, including one also linked to prostate cancer. The study provides insights into the mechanisms controlling glucose levels in the blood, offering potential new methods for preventing or treating the disease.
A new study published in Radiology found that MRI detection of extracapsular extension is an important factor in determining outcome for men scheduled to undergo radiation therapy. Patients with substantial extracapsular spread are more likely to experience recurrence and spread of their cancers.
A multi-center study found that prostate size and urinary symptoms influence patient satisfaction with cancer treatment. Men with larger prostates may experience improved urination after surgery, while African-American men tend to be less satisfied despite receiving similar care.
A new study found that improved biopsy techniques have reduced the correlation between prostate-specific antigen (PSA) levels and positive biopsy results in men with a normal digital rectal exam. The study suggests that PSA tests are less useful for prostate cancer screening, highlighting the need for new diagnostic markers.
Researchers at Thomas Jefferson University have discovered that blocking the signaling protein Stat5 can effectively kill prostate cancer cells and inhibit tumor growth. This finding holds promise for treating advanced prostate cancer, particularly hormone-resistant cases.
A new blood biomarker has been discovered that enables accurate prediction of prostate cancer metastasis. The biomarker, endoglin, measures plasma levels associated with an increased risk of cancer spread into regional lymph nodes. Adding this marker to current methods improves accuracy from 89.4% to 97.8%.
A five-year grant aims to uncover the genetic mechanism behind increased sensitivity to estrogen due to low-dose BPA exposure, which may predispose men to prostate cancer later in life. The study will use human prostate-like structures and animal models to characterize dose-response and gene modifications.
Researchers at UCLA's Jonsson Cancer Center found that hormone refractory prostate cancers are more invasive and likely to spread to other organs than androgen-dependent cancers. The study suggests that blocking overexpression of the androgen receptor could prevent cancer spread.
Researchers found that mildly obese men's PSA scores were fourteen percent lower than normal-weight men, while moderately and severely obese men had 29 percent lower PSA values. The study highlights the need to reconsider PSA threshold values for heavier patients to ensure timely diagnosis.
Researchers discovered a correlation between pre-treatment biopsy samples and post-treatment positive biopsies in high-risk prostate cancer patients. This information can help doctors tailor radiation treatment to reduce recurrence rates.
Researchers found that a single PSA test before age 50 can predict advanced prostate cancer up to 25 years later, helping identify high-risk men for targeted screenings. The study analyzed blood samples from over 160 men with advanced prostate cancer and a similar cohort without cancer.
Researchers found a biomarker that identifies men with a five-fold increased risk of prostate cancer recurrence if their tumors show silencing of the CDH13 gene. The study, which examined DNA methylation changes in 151 research subjects, suggests a potential tool to improve prediction accuracy and inform clinical practice.
Researchers found a single PSA test can predict advanced prostate cancer with high accuracy, allowing for targeted screening and potentially reducing overdiagnosis. The study revealed that men with higher PSA levels are at increased risk of developing advanced cancer, highlighting the potential for early detection to improve outcomes.
A new study finds that eating a diet low in fat and red meat, but high in vegetables and lean protein, may significantly decrease the risk of symptomatic benign prostatic hyperplasia (BPH). This association is likely due to reduced inflammation and changes in steroid hormones.
Researchers found that men with physically active jobs had a lower risk of developing prostate cancer compared to those with low-activity jobs. The study also revealed that increased physical activity was associated with reduced exposure to carcinogenic chemicals.
Researchers at Henry Ford Hospital are conducting a phase III clinical trial to determine the effectiveness of gene therapy in combination with radiation therapy for patients with intermediate risk prostate cancer. The trial aims to improve patient outcomes by delaying hormone therapy, which can have severe side effects.
Localized prostate cancer treatment options face uncertainty due to limited evidence. Gene expression tests for breast cancer hold promise but require further data on benefits and limitations. New HIV treatment guidelines suggest earlier initiation may increase life expectancy for younger patients. Pregnant women should not be screened...
A new urine test detects prostate cancer more accurately than current methods, including PSA and PCA3 tests. The test identified 80% of patients with prostate cancer and was 61% effective in ruling out disease.
Researchers have developed a successful test vaccine that prevents the development of prostate cancer in 90% of young mice. The vaccine targets prostate stem cell antigen (PSCA), which is over-expressed in early-stage prostate cancers, and has been shown to mount an immune response against the protein.
A new model predicts prostate cancer progression based on Gleason score and biomarker assessments, providing valuable information for patient management and treatment planning. The research has potential benefits for patients diagnosed with early prostate cancer.
A recent study published in The Prostate found that men with low zinc levels and high cadmium exposure had a 22% higher PSA level, indicating a higher risk of prostate cancer. Conversely, those with high zinc intake showed little evidence of an association between cadmium and PSA levels.
Men with prostate cancer who undergo radical prostatectomy experience significant urinary and sexual dysfunction, including incontinence and depression. Health-care practitioners must educate patients about these side effects to improve quality of life.
A multidisciplinary team led by Dr. Neil Bander will develop a novel nanomedicine for prostate cancer, targeting specific sites with high PSMA presence. The collaboration aims to create synergies in research and development, potentially reducing side effects and increasing effectiveness.
A collaborative analysis of 18 prospective studies found no link between circulating sex hormones and prostate cancer risk. High levels of male sex hormones were previously thought to be a risk factor, but the results indicate that testosterone and estrogen do not play a significant role in prostate cancer development.
A molecular change found in human prostate cancers triggers growth of prostate cancer in mice and human cell lines. The overexpression of ERG transcription factor is thought to activate cell-invasion programs, displacing basal cells by neoplastic epithelium.